David Amsellem

Stock Analyst at Piper Sandler

(0.1)
# 2088
Out of 5,240 analysts
168
Total ratings
48.08%
Success rate
3.85%
Average return
42 Stocks
Name Action Price Target Current % Upside Ratings Updated
Intra-Cellular Thera...
Downgrades: Neutral
107 132
126.84 4.07% 1 Jan 14, 2025
Avadel Pharmaceutica...
Maintains: Overweight
24 13
8.03 61.89% 5 Jan 10, 2025
Sage Therapeutics
Maintains: Overweight
26 9
7.46 20.64% 1 Jan 2, 2025
Amgen
Maintains: Overweight
344 310
267 16.1% 1 Jan 2, 2025
Neurocrine Bioscienc...
Reiterates: Overweight
160 160
139.49 14.7% 8 Dec 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
163 163
123.1 32.41% 9 Dec 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
13 14
11.71 19.56% 6 Dec 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
45 15
5.02 198.8% 2 Nov 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 11
7.86 39.95% 4 Nov 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
3 3
3.21 -6.54% 4 Nov 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
38 37
28.5 29.82% 7 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
15 16
11.23 42.48% 4 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
37 37
33.15 11.61% 6 Oct 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
68
54.22 25.41% 1 Oct 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
38 67
51.62 29.79% 5 Sep 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
41 36
37.85 -4.89% 12 Sep 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
11 6
3.29 82.37% 8 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
71 66
38.47 71.56% 5 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
9 3
7.47 -59.84% 7 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
42 42
20.55 104.38% 7 Jul 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
19 20
21 -4.76% 9 May 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
22 24
15.84 51.52% 5 Apr 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
10
3.04 228.95% 1 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 21
3.65 475.34% 3 Feb 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
90 113
84.66 33.48% 3 Jan 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
33 45
n/a n/a 2 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
144 12
4.71 154.78% 3 Nov 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
72 42
36.42 15.32% 3 Oct 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
26 17
0.65 2515.38% 3 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
285
n/a n/a 1 Jan 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
90 110
n/a n/a 5 Dec 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
3750 250
n/a n/a 2 May 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
6 6
n/a n/a 2 Apr 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
5 3
n/a n/a 5 Mar 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
5 6
n/a n/a 2 Feb 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 8
n/a n/a 1 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
23 17
n/a n/a 1 Apr 15, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
9
n/a n/a 4 Oct 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
n/a
n/a n/a 2 Mar 9, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
n/a
n/a n/a 2 Jul 18, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
n/a
n/a n/a 5 May 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
12
n/a n/a 1 Dec 19, 2016